Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

marketwatch.com - Sumitomo Dainippon Pharma FY Net Y106.87B Vs Net Y23.63B
Sumitomo Dainippon Pharma FY Net Y106.87B Vs Net Y23.63B
MarketWatch

Sumitomo Dainippon Pharma Co. Ltd. (4506.TO) Japan Year Ended March 31 GROUP 2026 2025 Revenue Y453.29 bln Y398.83 bln Operating Profit Y107.34 bln Y28.80 bln Net Profit Y106.87 bln Y23.63 bln Per share Earnings Y268.99 Y59.49 Results are based on…

chron.com - MATTHEW PERRONE and SEUNG MIN KIM - Trump FDA chief is leaving after angering pharma CEOs, vaping lobbyists and anti-abortion groups
Trump FDA chief is leaving after angering pharma CEOs, vaping lobbyists and anti-abortion groups
Chron

WASHINGTON (AP) — The head of the Food and Drug Administration, Dr. Marty Makary, is resigning after a rocky tenure that drew months of complaints from health industry executives, anti-abortion activists, vaping lobbyists and other allies of…

wsj.com - AdriĆ  Calatayud - Roche CEO Expects Pharma Portfolio to Deliver Sales Growth Through 2030
Roche CEO Expects Pharma Portfolio to Deliver Sales Growth Through 2030
Wall Street Journal

Holding expects drugs it already has on the market and a trio of medicines due to be launched shortly to deliver sales growth for its pharmaceutical business through the end of the decade, its chief executive said. The Swiss drugmaker's on-market…

fool.com - Jonathan Ponciano - What to Know About This Fund's Sale of a Pharma Stock Up 56% in a Year
What to Know About This Fund's Sale of a Pharma Stock Up 56% in a Year
The Motley Fool

On May 12, 2026, Quantedge Capital disclosed in an SEC filing that it sold out its entire stake in Supernus Pharmaceuticals (SUPN +2.24%) during the first quarter, with an estimated transaction value of $4.56 million based on quarterly average…

seekingalpha.com - SA Transcript Insights Editor - OptimizeRx forecasts $95M-$100M 2026 revenue while maintaining $21M-$25M adjusted EBITDA amid pharma MFN disruption (NASDAQ:OPRX)
OptimizeRx forecasts $95M-$100M 2026 revenue while maintaining $21M-$25M adjusted EBITDA amid pharma MFN disruption (NASDAQ:OPRX)
Seeking Alpha

Due to continued softness in contracted revenue linked to MFN pricing disruption, more cautious customer budgets, shorter contract durations, and disruption at one major client. DSP integration is seen as a major strategic shift, enabling access to…

ciol.com - Deepali Jain - Startup SwishX Launches Agentic AI Platform for Pharma, Raises $2.2 Million Seed Funding
Startup SwishX Launches Agentic AI Platform for Pharma, Raises $2.2 Million Seed Funding
CIOL

Bengaluru-based startup SwishX has launched what it called the world's first Agentic AI platform built exclusively for pharmaceutical and medtech companies, as healthcare and life sciences firms increasingly turn to artificial intelligence (AI) to…

seekingalpha.com - SA Transcripts - aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript
Seeking Alpha

aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results May 11, 2026 4:30 PM EDT Ashlee Dunston - Director of Investor Relations & Corporate Communications Sanjay Shukla -…

statnews.com - Ed Silverman - Pharmalittle: We're reading about pharma lobbying, Bristol's deal with a Chinese partner, and more
Pharmalittle: We're reading about pharma lobbying, Bristol's deal with a Chinese partner, and more
STAT

Top of the morning to you, and a fine one it is. Sunny skies and mild breezes are enveloping the Pharmalot campus once again. Who could ask for anything more? Actually, we could. Specifically, we would like another cup of stimulation. So off we go…

mymotherlode.com - AP News - Trump FDA chief is leaving after angering pharma CEOs, vaping lobbyists and anti-abortion groups
Trump FDA chief is leaving after angering pharma CEOs, vaping lobbyists and anti-abortion groups
myMotherLode.com

Published May 12, 2026 11:14 am WASHINGTON (AP) — The head of the Food and Drug Administration, Dr. Marty Makary, is resigning after a rocky tenure that drew months of complaints from health industry executives, anti-abortion activists…

marketbeat.com - BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
MarketBeat

BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope BridgeBio Pharma NASDAQ: BBIO executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline…

thehindubusinessline.com - Torrent Pharma says JB Chemicals merger in final phase, expects completion in 1-2 months
Torrent Pharma says JB Chemicals merger in final phase, expects completion in 1-2 months
BusinessLine

Torrent Pharmaceuticals said the merger process of Mumbai-based JB Chemicals & Pharmaceuticals Ltd with the company has entered its final stage, with a hearing scheduled in the second week of June and the transaction expected to become effective…

mediamatters.org - Written by Noah Dowe & Alyssa Tirrell - New reporting links skepticism of the vitamin K shot to newborn deaths. Influencers and media figures have been fearmongering about the shot for years.
New reporting links skepticism of the vitamin K shot to newborn deaths. Influencers and media figures have been fearmongering about the shot for years.
Media Matters for America

Alex Jones of the now-defunct site Infowars: “They try to give them a vitamin K shot at birth to thicken the blood quicker. That's got a lot of issues with it.” He added of vaccines generally, “It really messes little babies up…

thehill.com - Nathaniel Weixel - FDA Commissioner Marty Makary resigns
FDA Commissioner Marty Makary resigns
The Hill

Food and Drug Administration (FDA) Commissioner Marty Makary officially stepped down from his role on Tuesday. Makary managed to anger just about every constituency, from the pharma and biotech industries to the anti-abortion movement, but the end…

benzinga.com - Sweta Killa - Bristol Myers Squibb Strikes $15.2 Billion Drug Development Deal With Hengrui Pharma - Bristol-Myers Squi
Bristol Myers Squibb Strikes $15.2 Billion Drug Development Deal With Hengrui Pharma - Bristol-Myers Squi
Benzinga

Bristol-Myers Squibb Co. (NYSE:) on Tuesday announced a partnership with Hengrui Pharma to develop a portfolio of 13 early-stage programs spanning oncology, hematology and immunology. The deal follows the company's earlier success with Sotyktu, an…

republicworld.com - Shourya Jha - Market Volatility: Sensex and Nifty Stagnant; Banking Drags as Titan Leads Sectoral Sell-off
Market Volatility: Sensex and Nifty Stagnant; Banking Drags as Titan Leads Sectoral Sell-off
Republic World

The NSE Nifty 50 opened at 23,362.45 and hit an intraday high of 23,503.80 before settling near 23,399.45. Despite the marginal 0.09% gain, the advance-decline ratio favored bears, with nearly 2,711 stocks declining against 584 advances on the…

Receive a Daily briefing on Pharma Industry News

Get Started